Saturday 17 October 2026
Export APVO’s income statement to Excel — free account
Aptevo Therapeutics Inc.
APVO Healthcare Biotechnology
Aptevo Therapeutics Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.1 million. In the quarter to June 2026, EPS grew 96.5% and free cash flow grew 23.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.62
0.08
−4.71%
Follow APVO
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 6.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.92 | — | — | — |
Piotroski F-Score |
2 | 6 | 2 | 3 | 3 | 3 | 4 | — | — | — |
P/S ratio |
41,578,223.25 | 56,728,401.70 | 10,164,405.30 | 483,499.54 | 5,460,128.21 | 1,759,124.90 | 527,133.51 | — | — | — |
Altman Z-Score |
5,887,741.41 | 12,734,392.50 | 3,793,066.32 | 226,288.86 | 1,182,655.11 | 234,243.36 | 256,174.47 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(8.03) | 1.60 | (7.42) | (16.11) | (10.27) | (12.78) | (20.50) | — | — | — |
Beneish M-Score |
— | 1.13 | (1.47) | — | (3.75) | (2.01) | 3.69 | — | — | — |
P/Operating CF |
(62,289,356.22) | (53,921,594.71) | (32,153,364.93) | (3,073,919.44) | (11,895,820.73) | (5,572,980.22) | (1,152,522.07) | — | — | — |
P/B ratio |
8,210,231.36 | 10,136,221.27 | 7,711,054.96 | 1,323,846.41 | 4,389,424.51 | 17,782,206.63 | 380,818.33 | — | — | — |
Price to Tangible BV |
9,509,770.92 | 10,947,599.40 | 9,320,334.59 | 2,173,134.07 | 6,087,089.28 | 0.00 | 512,874.91 | — | — | — |
EV/Sales |
41,578,219.60 | 56,728,397.46 | 10,164,404.99 | 483,499.87 | 5,460,126.90 | 1,759,122.38 | 527,132.03 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(11,262,506.72) | (20,001,559.91) | (4,559,572.36) | (369,888.87) | (2,484,415.47) | (997,422.96) | (325,602.20) | — | — | — |
EV/FCF |
(10,543,976.30) | (19,349,036.65) | (4,474,642.73) | (368,558.40) | (2,476,980.64) | (965,663.29) | (323,341.18) | — | — | — |
Quick Ratio |
2.83 | 4.50 | 2.04 | 0.51 | 3.09 | 1.44 | 2.89 | 2.34 | 1.40 | 3.57 |
Current Ratio |
3.65 | 5.14 | 2.76 | 0.78 | 3.25 | 1.51 | 3.15 | 2.64 | 1.72 | 3.82 |
Net Debt/EBITDA |
0.27 | 1.22 | 0.23 | (0.28) | 0.67 | 1.53 | 0.69 | 0.60 | 0.36 | 0.83 |
Debt/Assets |
20.01% | 16.29% | 28.56% | 43.42% | 46.79% | 27.16% | 10.10% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.36 | 0.23 | 0.63 | 1.96 | 1.51 | 12.64 | 0.19 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.09 | 0.14 | 0.25 | 0.54 | 0.08 | 0.22 | 0.07 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.33 | (5.96) | 0.96 | 1.05 | 1.65 | 0.76 | (2.62) | 0.67 | 0.99 | 0.93 |
Capex/Depreciation |
(0.75) | (0.45) | (0.41) | (0.07) | (0.06) | (0.62) | (0.03) | 0.00 | 0.00 | 0.00 |
| (161.53%) | 10.52% | (95.50%) | (191.48%) | (124.84%) | (319.56%) | 83.66% | (115.32%) | (284.28%) | (248.81%) | |
| (102.37%) | 6.68% | (58.20%) | (66.91%) | (33.19%) | (51.67%) | 17.68% | (58.96%) | (119.36%) | (128.73%) | |
ROIC |
(618.46%) | (169.33%) | (169.51%) | (113.36%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(194.56%) | 8.46% | (147.98%) | 941.09% | (49.94%) | (140.93%) | 39.73% | (136.70%) | (483.08%) | (158.87%) |
Average Days of Receivables |
11.22 | 53.31 | 82.60 | 79.05 | 200.67 | 108.80 | 293.03 | — | — | — |
Research and Development Expense of Revenue |
291.64% | 197.99% | 153.40% | 76.37% | 414.30% | 154.52% | 574.25% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
362.12% | 235.88% | 121.96% | 49.96% | 323.76% | 119.57% | 445.50% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.08 | 0.05 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
38.15% | 33.32% | 9.28% | 4.93% | 29.13% | 13.37% | 57.87% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Graham Number |
0.00 | 22,993.77 | 0.00 | 0.00 | 0.00 | 0.00 | 10,732.45 | — | — | — |
Earnings Yield |
(168.17%) | 15.68% | 0.00% | (134.66%) | (3.23%) | (60.00%) | 108.23% | — | — | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Revenue per Share |
0.49 | 0.69 | 1.03 | 11.12 | 1.27 | 2.62 | 0.61 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.82) | (1.95) | (2.29) | (14.53) | (8.65) | (4.62) | (4.12) | 0.00 | (29,731.25) | (81.12) |
Capex per Share |
(0.12) | (0.07) | (0.04) | (0.05) | (0.03) | (0.15) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.95) | (2.01) | (2.33) | (14.58) | (8.67) | (4.78) | (4.13) | 0.00 | (29,731.25) | (81.12) |
Cash per Share |
2.71 | 3.81 | 1.36 | 4.27 | 12.54 | 9.88 | 4.44 | 0.00 | 10,892.50 | 68.52 |
Shareholders Equity per Share |
2.50 | 3.85 | 1.35 | 4.06 | 4.89 | 0.26 | 3.52 | 0.00 | 5,943.75 | 55.09 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.50 | 3.85 | 1.35 | 4.06 | 4.89 | 0.26 | 3.52 | 0.00 | 5,943.75 | 55.09 |
Free Cash Flow |
(39.37) | (42.97) | (52.40) | (42.54) | (29.41) | (22.39) | (21.05) | (11.73) | (23.78) | (25.59) |
Working Capital |
51.87 | 76.57 | 31.08 | (8.24) | 32.73 | 17.81 | 18.74 | 11.84 | 4.45 | 17.03 |
Capital Expenditures |
(2.51) | (1.40) | (0.98) | (0.15) | (0.09) | (0.71) | (0.03) | — | — | — |
Net Current Asset Value |
30.12 | 60.11 | 11.60 | (11.57) | 10.31 | (2.81) | 11.21 | 6.45 | (0.18) | 13.27 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.25 | 0.10 | 0.04 | 0.00 | 0.02 | 0.06 | 0.01 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.57 | 0.54 | 0.46 | 0.57 | 0.50 | 0.48 | 0.62 | 0.63 | 0.65 | 0.79 |
Cash ROIC |
(31.79%) | (23.58%) | (65.24%) | (89.59%) | (34.93%) | (35.60%) | (47.77%) | (40.27%) | (176.59%) | (65.62%) |
Accounts Receivable Turnover |
2.45 | 11.98 | 6.27 | 5.30 | 0.92 | 4.07 | 1.01 | — | — | — |
Accounts Payable Turnover |
1.21 | 0.56 | 1.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
1.20 | 6.73 | 7.97 | 0.00 | — | — | 0.00 | — | — | — |
Average Days of Payables |
307.94 | 535.48 | 379.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
13.50 | 74.89 | 58.10 | 1,002.57 | — | — | 0.00 | — | — | — |
Average Receivables |
4.07 | 1.22 | 3.68 | 6.12 | 4.70 | 3.02 | 3.08 | — | — | — |
Average Payables |
10.30 | 8.93 | 9.51 | 9.05 | 6.01 | 4.52 | 3.48 | 3.74 | 2.61 | 1.06 |
Average Inventory |
10.39 | 0.74 | 1.41 | 3.96 | — | — | — | — | — | — |
Average Assets |
109.81 | 104.43 | 92.25 | 60.45 | 53.48 | 55.07 | 45.41 | 29.53 | 20.22 | 21.39 |
Average Common Equity |
69.59 | 66.30 | 56.22 | 21.12 | 14.22 | 8.91 | 9.60 | 15.10 | 8.49 | 11.07 |
Columns are period end dates